Replay available

Immunic, Inc. (IMUX) Q3 2023 Earnings Call

Immunic, Inc. (NASDAQ: IMUX) Q3 2023 earnings conference call, held 2023-11-14. Replay captured from the company's public earnings webcast.

Tue, November 14, 2023 at 8:00 AMendedReplay
Immunic, Inc.  (IMUX) Q3 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dr. Daniel Fitt

Chief Executive Officer and President

Glenn Whaley

Chief Financial Officer

Caroline Pocher

Analyst, Wedbush PacGrow

Liam Heaster

Analyst, Piper Sandler

Matt Kaplan

Analyst, Ladenburg Thalmann

Tom Smith

Analyst, Leerink Partners

Mayank Mamthani

Analyst, B. Riley Securities

Replay transcript excerpt

Good morning and welcome to Munich's third quarter 2023 earnings call. My name is Jessica Bru, head of investor relations and communications at the Munich. I will also be the moderator on today's call. Speaking on the call are Dr. Daniel Fitt, our chief executive officer and president, as well as Glenn Whaley, our chief financial officer. Please note that all participants will be in this nonly mode and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. If you join the webcast via the Zoom platform, there are two ways to submit questions. You can either submit your questions in writing via the Q&A tool of the Zoom portal, or if you would like to speak with us directly, please use the raise hand function in the Zoom portal to queue your question. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunex's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunix's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information of future events. Please refer to Immunix's SEC filings for a more detailed description of the risk factors that may affect Immunix's results and these forward-looking statements. I would now like to turn the call over to our CEO and President, Dr. Daniel Fitt, to begin the presentation. Daniel? Yeah, thank you, Jessica. I would...

More from Immunic, Inc.